Asia Market Selloff, Biotech Investment Restrictions, and ETF Growth

Bloomberg's The China Show reviews the morning market session across Shanghai, Shenzhen, Hong Kong, and other Asian markets, focusing on a broad risk-off move, technology-sector weakness, and policy and corporate developments affecting investors. The program combines market updates with interviews and analysis on China's equity outlook, AI-related supply chains, biotech licensing, luxury retail, and exchange-traded funds.

■ Market and macro backdrop
- Mainland and Hong Kong equities under pressure; CSI 300 enters bear-market territory
- Rising oil prices, Treasury yields, and yen strength as haven demand increases
- Central bank decisions and upcoming bank earnings in focus

■ Corporate and regulatory developments
- SK Hynix scraps planned U.S. listing of its NAND flash unit
- U.S. Treasury proposal to restrict certain outbound investment in Chinese biotech
- CSRC reported to tighten scrutiny of spin-off listings

■ Sector and regional themes
- AI export boom and differing spillovers to China, Korea, and Taiwan
- Luxury retail and outlet-village strategies in China
- Active ETF adoption and BlackRock's Asia investor survey
- Brazil election and Taiwan typhoon market closures

The discussion is aimed at investors, market strategists, and viewers tracking Asia-Pacific equities, policy risk, and cross-border investment trends. It provides context for interpreting daily market moves and regulatory signals rather than specific investment recommendations.